Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US

References

• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Abuse-deterrent opioids – evaluation and labeling. Draft guidance. Rockville, MD: U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed October 14, 2013
   Google Scholar
• Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration/Center for Behavioral Health Statistics and Quality, 2012. http://www.samhsa.gov/data/NSDUH/2k11Results/NSDUHresults2011.htm. Accessed October 14, 2013
   Google Scholar
• Questions and answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics. Silver Spring, MD: U.S. Department of Health and Human Services/Food and Drug Administration, 2012. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm. Accessed October 14, 2013
   Google Scholar
• Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012;37:412-18
   PubMedGoogle Scholar
• Raffa RB, Pergolizzi JV, Muñiz E, et al. Designing opioids that deter abuse. Pain Res Treat 2012;2012:1-10
   Google Scholar
• Stanos S. Continuing evolution of opioid use in primary care practice: implications of emerging technologies. Curr Med Res Opin 2012;28:1505-16
   PubMed Web of Science ®Google Scholar
• FDA issues draft guidance on abuse-deterrent opioids. Silver Spring, MD: U.S. Department of Health and Human Services/Food and Drug Administration, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm. Accessed October 14, 2013
   Google Scholar
• Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-67
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009;7:61-70
   PubMedGoogle Scholar
• Skinner BJ. Net societal economic impact in Canada from withholding regulatory approval for generic OxyContin. Canadian Health Policy 2012;1-21
   Google Scholar
• FDA actions on OxyContin products, 4/16/2013. Silver Spring, MD: U.S. Department of Health and Human Services/Food and Drug Administration, 2013. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm347857.htm. Accessed October 14, 2013
   Google Scholar
• FDA approves abuse-deterrent labeling for reformulated OxyContin. Silver Spring, MD: U.S. Department of Health and Human Services/Food and Drug Administration, 2013. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm348252.htm Accessed October 14, 2013
   Google Scholar
• Leider HL, Dhaliwal J, Davis EJ, et al. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care 2011;17:32-40
   PubMed Web of Science ®Google Scholar
• Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8:573-82.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
   PubMedGoogle Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351-8
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187-9
   PubMed Web of Science ®Google Scholar
• Blazer DG, Wu L-T. Nonprescription use of pain relievers by middle-aged and elderly community-living adults: National Survey on Drug Use and Health. J Am Geriatr Soc 2009;57:1252-7
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Schiller M, et al. Economic impact of opioid abuse, dependence, and misuse. Am J Pharm Benefits 2011;3:e59-70
   Google Scholar
• Inciardi JA, Surratt HL, Cicero TJ, et al. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med 2009;10:537-48
   PubMed Web of Science ®Google Scholar
• Sessler NE, Downing JM, Kale H, et al. Effects of reformulating extended-release oxycodone on fatal adverse event reports. Poster presentation at PAINWeek 2012, Las Vegas, NV
   Google Scholar
• Vital signs: overdoses of prescription opioid pain relievers–United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-92
   Google Scholar
• FDA introduces new safety measures for extended-release and long-acting opioid medications. Silver Spring, MD: U.S. Department of Health and Human Services/Food and Drug Administration, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. Accessed October 14, 2013
   Google Scholar
• Sessler NE, Baumgartner TF, Coplan PM. Changes in number of spontaneous adverse event reports of drug abuse, intentional drug misuse, medication error, and overdose after reformulation of OxyContin. Poster presentation at PAINWeek 2012, Las Vegas, NV
   Google Scholar
• Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8:573-82
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444-59
   PubMed Web of Science ®Google Scholar